Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Osteoporosis is a prevalent skeletal disorder characterized by reduced bone mineral density and microarchitectural deterioration of bone tissue, resulting in bone fragility and low-trauma fractures. Imaging techniques are routinely used to detect low bone mass; however, they are unable to identify deterioration of bone quality. Recently, microRNAs have emerged as regulators of bone remodelling and potentially also as a new class of sensitive biomarkers of bone health to aid in diagnosis and treatment monitoring of osteoporosis.
To identify new plasma-based biomarkers associated with osteoporosis we analyzed microRNAs isolated from plasma samples of 74 postmenopausal women divided into osteoporotic (N = 17) and control groups (N = 57). A prior microRNA screening was performed where a few showed promise for further analysis. Quantitative polymerase chain reaction was used to investigate differences in expression of let-7d-5p, let-7e-5p, miR-30d-5p, miR-30e-5p, miR-126-3p, miR-148a-3p, miR-199a-3p, miR-423-5p and miR-574-5p between the two groups. Furthermore, correlation analysis between microRNA expression levels and patient bone mineral density measurements and fracture risk assessment tool (FRAX) as well as trabecular bone scores were performed.
Expression of miR-148a-3p was significantly higher (p = 0.042) in the osteoporotic patient group compared to the controls. In addition, we identified correlations between miR-126-3p (ρ = 0.253, p = 0.032) and 423-5p (ρ = −0.230, p = 0.049) and parameters of bone quality and quantity.
The results from our study, together with the functional role of miR-148a-3p in bone suggest that this microRNA could be considered as a potential new plasma-based biomarker for pathological changes associated with osteoporosis.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013; doi: 10.1007/s11657-013-0136-1.
Sun M, Zhou X, Chen L, Huang S, Leung V, Wu N, et al. The regulatory roles of microRNas in bone remodeling and perspectives as biomarkers in osteoporosis. Biomed Res Int. 2015;p:1652417.
Vrtačnik P, Marc J, Ostanek B. Epigenetic mechanism in bone. Clin Chem Lab Med. 2014;52(5):589–608. PubMed
Heilmeier U, Hackl M, Skalicky S, Weilner S, Schroeder F, Vierlinger K, et al. Serum microRNasare indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose-tissue derived mesenchymal stem cells in vitro. J Bone Miner Res. 2016; doi: 10.1002/jbmr.2897. PubMed
Wang Y, Fu B, Sun X, Li D, Huang Q, et al. Differentially expressed microRNAs in bone marrow mesenchymal stem cell-derived microvesicles in young and older rats and their effect on tumor growth factor-β1-mediated epithelial-mesenchymal transition in HK2 cells. Stem Cell Res Ther. 2015;6:185. CrossRefPubMedPubMedCentral
Costa M, Leitão A, Enguita F. MicroRNA profiling in plasma or serum using quantitative RT-PCR. Methods Mol Biol. 2014. doi: 10.1007/978-1-4939-1062-5_11.
- MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women
Simona Mencej Bedrač
- Springer Vienna